drugset / Trial / NCT06226350
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study was an open, single-arm, enriched, multicenter Phase II study.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2023-12-05
- Completion
- 2024-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F520 | Monoclonal antibody | 3 mg/kg | Intravenous |